Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor

• Published in: Cancer science Vol. 112; no. 5; pp. 1963 - 1974
• Main Authors: Nishiya, Naoyuki, Oku, Yusuke, Ishikawa, Chie, Fukuda, Tsutomu, Dan, Shingo, Mashima, Tetsuo, Ushijima, Masaru, Furukawa, Yoko, Sasaki, Yuka, Otsu, Keishi, Sakyo, Tomoko, Abe, Masanori, Yonezawa, Honami, Ishibashi, Fumito, Matsuura, Masaaki, Tomida, Akihiro, Seimiya, Hiroyuki, Yamori, Takao, Iwao, Masatomo, Uehara, Yoshimasa
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2021; John Wiley and Sons Inc
• Subjects: Acrylamides - pharmacology; Alkaloids; Aniline Compounds - pharmacology; Animals; Biological activity; Cancer therapies; Cell Line, Tumor; Cell Proliferation - drug effects; Chemical bonds; Cloning; Cytokines; Drug development; Drug resistance; Drug Resistance, Neoplasm - genetics; Drug Screening Assays, Antitumor - methods; Enzyme inhibitors; Epidermal growth factor; epidermal growth factor receptor; Epidermal growth factor receptors; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; ErbB Receptors - metabolism; Fluoroacetates; Gene Expression; Heterocyclic Compounds, 4 or More Rings - chemistry; Heterocyclic Compounds, 4 or More Rings - pharmacology; Heterografts; Humans; Kinases; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Mollusca - chemistry; Mutagenesis; Mutagenesis, Site-Directed; Mutants; Mutation; Original; Phosphorylation; Plasmids; Protein Kinase Inhibitors - chemistry; Protein Kinase Inhibitors - pharmacology; Protein-tyrosine kinase; Proteins; recurrence; topoisomerase inhibitor; tyrosine kinase inhibitor; Xenografts; lung cancer; recurrence; tyrosine kinase inhibitor; epidermal growth factor receptor; topoisomerase inhibitor
• ISSN: 1347-9032; 1349-7006; 1349-7006
• DOI: 10.1111/cas.14839

The emergence of acquired resistance is a major concern associated with molecularly targeted kinase inhibitors. The C797S mutation in the epidermal growth factor receptor (EGFR) confers resistance to osimertinib, a third‐generation EGFR‐tyrosine kinase inhibitor (EGFR‐TKI). We report that the derivatization of the marine alkaloid topoisomerase inhibitor lamellarin N provides a structurally new class of EGFR‐TKIs. One of these, lamellarin 14, is effective against the C797S mutant EGFR. Bioinformatic analyses revealed that the derivatization transformed the topoisomerase inhibitor‐like biological activity of lamellarin N into kinase inhibitor‐like activity. Ba/F3 and PC‐9 cells expressing the EGFR in‐frame deletion within exon 19 (del ex19)/T790M/C797S triple‐mutant were sensitive to lamellarin 14 in a dose range similar to the effective dose for cells expressing EGFR del ex19 or del ex19/T790M. Lamellarin 14 decreased the autophosphorylation of EGFR and the downstream signaling in the triple‐mutant EGFR PC‐9 cells. Furthermore, intraperitoneal administration of 10 mg/kg lamellarin 14 for 17 days suppressed tumor growth of the triple‐mutant EGFR PC‐9 cells in a mouse xenograft model using BALB/c nu/nu mice. Thus, lamellarin 14 serves as a novel structural backbone for an EGFR‐TKI that prevents the development of cross‐resistance against known drugs in this class. The emergence of acquired resistance is a major concern associated with molecularly targeted kinase inhibitors. We report that the derivatization of the marine alkaloid topoisomerase inhibitor lamellarin N provides a structurally new class of epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs). One of these EGFR‐TKIs, lamellarin 14, is effective against the C797S mutant EGFR.